European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus®)
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Aptivus ® for the suppression of HIV in highly treatment experienced patients who have developed resistance to other protease inhibitors.
Novo Nordisk researchers nominated for Europe's top innovation prize
- Details
- Category: Novo Nordisk
A team of researchers from Novo Nordisk is nominated for Europe's top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.
GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) announced that Fountain Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT) (Sirtris), for $22.50 in cash without interest and less any required withholding taxes.
Abbott, Takeda Conclude TAP Joint Venture
- Details
- Category: Abbott
Abbott and Takeda Pharmaceutical Company Limited have concluded their TAP Pharmaceutical Products Inc. (TAP) joint venture. The closing of the agreement to evenly divide the value of the more than 30-year-old joint venture marks the conclusion of one of the most successful joint ventures in the history of American business.
Esperion Therapeutics Completes $22.75 M Series A Financing
- Details
- Category: Pfizer
Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular and metabolic disease, today announced that it has been launched as a privately held, independent enterprise.
Lundbeck expands geographical rights for Circadin®
- Details
- Category: Lundbeck
H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. announced that Lundbeck has obtained expanded exclusive rights to commercialize Circadin® in Asia, Latin America and other major markets such as Australia and Turkey. Following regulatory filing and approval Lundbeck expects to market Circadin® in the first markets outside of Europe in 2009.
AstraZeneca Submits sNDA for SYMBICORT® for COPD Treatment
- Details
- Category: AstraZeneca
AstraZeneca today announced submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) to seek approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
More Pharma News ...
- Novo Nordisk will donate a licence to its small molecule compound library
- Follicular lymphoma: EU approval for Zevalin® as First-Line Consolidation Treatment
- Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12
- Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology
- Two Merck Medicines Recommended for Approval in the European Union
- GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million
- AstraZeneca PLC First Quarter Results 2008